By studying the transcription of inducible HIF1A-AS2 (hypoxia inducible factor 1 subunit alpha antisense RNA 2), there is hope for a new method for ovarian cancer treatment that combines effective anticancer therapy with OC standard-of-care chemotherapy [40]. Here, HIF1A is linked to ovarian carcinoma.